Centre Hospitalier Valence — Clinical Trial Site

42 Registered trials

15 Currently recruiting

Organisation

Centre Hospitalier Valence

Location

Valence, France

Identifier

ORG-100042394

Address

179 Boulevard Marechal Juin, 26000, France

Departments

Département de dermatologie
dermatologie
Dermatology Department
gastro enterology
Gastro-Entérologie
Gastroentérologie
gastroenterology
Gastroenterology department
Head and neck surgery
Hématologie
hématologie et oncologie médicale
Hematology
Hepato Gastro-Entérologie
Hépato-Gastro-Entérologie
Hepato-gastroenterology
hepatogastroenterology
Maladies infectieuses
Medical oncology
Neurology
Onco-Hematology
ONCOLOGIE
oncology
Service d' Hépato-Gastro-Entérologie
Service d'hématologie
Service d'hématologie oncologie
Service d'oncologie médicale
Service de dermatologie
Service de Pneumologie
Service de Réanimation
Service Neurologie

Clinical trials at this site (42)

Search interface

Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran… Ended

2024-514876-41-00 Higher-risk myelodysplastic syndromes untreated and ine 9 2023-12-06
A Study to Evaluate Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic He… Ended

2023-503422-39-00 Hepatocellular Carcinoma (HCC) 5 2023-10-20
A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended

2022-501576-25-00 Melanoma 5 2023-07-07
PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien… Ended

2022-501217-31-00 Hepatocellular carcinoma 10 2023-03-09
A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended

2024-514502-31-00 Prurigo Nodularis 5 2021-01-11
A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su… Ended

2024-514088-25-00 Multiple Myeloma 5 2019-10-07
Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin wi… Ended

2024-515946-17-00 Non Small Cell Lung Cancer 5 2019-07-22
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513206-65-00 resected squamous cell carcinoma of head and neck 5 2018-08-10
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended

2024-517489-41-00 High-risk stage III colon cancer 5 2017-03-27
Comparing two treatment regimen for sinuses tumors and salivary glands: radiotherapy versus chemoradiotherapy Ended

2024-513972-16-00 - Resected tumors of sinuses or salivary glands - Non-o 5 2017-01-30
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
Clinical trial of MK-7648A in adults and children with skin cancer Ended

2022-501417-31-01 melanoma 5 2023-08-01
Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight… Ended

2023-509668-11-00 Moderate-to-severe plaque psoriasis and a body weight ≥ 6 2022-06-15
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended

2024-511996-13-00 Previously untreated, unresectable, or metastatic melan 5 2022-05-11
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended

2022-500395-57-00 Resectable high-risk Locally Advanced Cutaneous Squamou 5 2019-03-04
A RANDOMIZED TRIAL TESTING EARLY VERSUS LATE ONSET OF EPO ALFA TREATMENT IN LOWER RISK MDS WITH NON RBC TRANSFUSION DEPENDENT ANEMIA AND WI… Ended

2024-515356-21-00 Adult subject (18 years of age older) with low or inter 5 2018-04-17
A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym… Ended

2023-507271-21-00 Follicular Lymphoma 5 2017-04-11